Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Volume 21 Issue 3, March 2022

Immune targets for antidepressants, inspired by the Review on p224.

Cover design: S. Harris


  • Translation Together, a transnational consortium of translational research organizations, reflects on successes and challenges in regional COVID-19 pandemic responses and proposes five priorities to improve preparedness for future global public health crises and improve the global approach to translational research and science.

    • Kanny K. Wan
    • Danielle Davis
    • Christine M. Cutillo


Top of page ⤴

News & Analysis

Top of page ⤴

Research Highlights

Top of page ⤴


  • Targeted protein degradation with proteolysis-targeting chimeras (PROTACs) has the potential to tackle disease-causing proteins that have historically been highly challenging to target with conventional small molecules. This article summarizes the first two decades of PROTAC discovery and discusses key areas for the future of this therapeutic modality, including establishing the target classes for which it is most suitable and extending its application beyond oncology.

    • Miklós Békés
    • David R. Langley
    • Craig M. Crews
    Review Article
  • The development of therapies that are capable of safely achieving sizeable and sustained body weight loss has proved tremendously challenging. Here, Müller et al. provide an overview of the history of anti-obesity drug development, focusing on lessons learned, ongoing challenges and recent advances in the field.

    • Timo D. Müller
    • Matthias Blüher
    • Richard D. DiMarchi
    Review Article
  • Accumulating evidence suggests that, for some people, major depressive disorder has immunological roots. Here, Manji and colleagues discuss the progress towards immune-based treatments for depression, including which biomarkers might be most useful, as well as potential challenges to this approach.

    • Wayne C. Drevets
    • Gayle M. Wittenberg
    • Husseini K. Manji
    Review Article
Top of page ⤴


Quick links